Statistical Significance vs. Commercial Importance in Pharma Media
Interpret pharma media tests using effect size, uncertainty, power, decision thresholds, scalability, and commercial value.
The short answer
Statistical significance addresses how compatible the data are with a null model under stated assumptions. Commercial importance asks whether the plausible effect is large, durable, scalable, and valuable enough to change investment. A sound decision needs both, plus study validity.
Read the estimate in this order
- Design validity: Was the comparison credible?
- Effect size: How large is the absolute and relative difference?
- Uncertainty: What range is compatible with the data?
- Commercial threshold: What effect would justify action?
- Scalability: Will audience and supply remain similar at more spend?
| Pattern | Interpretation | Possible action |
|---|---|---|
| Precise, economically strong | Evidence supports action | Scale in stages |
| Precise, economically weak | Real but not valuable enough | Stop or redesign |
| Uncertain, potentially strong | Promising but unresolved | Extend or replicate |
| Uncertain, economically weak | Little decision value | Stop |
Avoid binary p-value management
A threshold does not turn evidence from false to true. Report confidence intervals and absolute outcomes. A non-significant result can reflect low power; a significant result can be trivial with a very large sample. The American Statistical Association cautions against scientific or business decisions based only on whether a p-value crosses a specific threshold (ASA).
Set the commercial threshold in advance
Estimate contribution after media, data, technology, measurement, and operational costs. Include uncertainty in prescription value, persistence, and scale. Finance and commercial teams should own value assumptions; media teams should not manufacture them after seeing results.
Hypothetical example
A study estimates 120 incremental prescriptions with a 95% interval from 20 to 220. If break-even is 80, the point estimate clears the threshold but the interval includes a commercially weak outcome. A staged scale or replication may be more rational than full rollout. The numbers are illustrative.
Guard against multiplicity
Many partners, audiences, outcomes, and weekly looks increase the chance of a favorable result by chance. Preselect a primary outcome and limit confirmatory comparisons. Label subgroup exploration as exploratory unless designed and powered otherwise.
Practical takeaway
Replace “Was it significant?” with “What effects remain plausible, and which decision is best under that uncertainty?” The next step is to add the commercial break-even line and confidence interval to every outcome readout.
Sources
- American Statistical Association, Statement on Statistical Significance and P-Values
- NIST/SEMATECH, Confidence Intervals
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.